EU to pilot new risk-based model for postmarket drug testing
This article was originally published in SRA
Executive Summary
The EU Heads of Medicines Agencies has endorsed plans to test a new risk-based model for identifying human and veterinary medicinal products that could be subjected to laboratory testing in the post-authorization phase under ongoing surveillance testing programs1.